Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4072352 | 0.94 | HPGD (0.49) | POLBALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL7898468 | 0.78 | HPGD (0.46) | SMN1; SMN2NPC1RAB9AHPGDTHRB | |
| SCHEMBL8502825 | 0.77 | THRB (0.54) | POLBALDH1A1NPC1RAB9AHPGD | |
| SCHEMBL7015486 | 0.77 | THRB (0.54) | POLBNPC1RAB9AHPGDTHRB | |
| SCHEMBL9081205 | 0.75 | USP5 (0.47) | POLBSMN1; SMN2NPC1RAB9ATHRB | |
| SCHEMBL30416115 | 0.74 | ALDH1A1 (0.68) | POLBALDH1A1SMN1; SMN2RAB9AHPGD | |
| Hydrochloric Acid SCHEMBL9084040 | 0.73 | USP5 (0.46) | POLBSMN1; SMN2NPC1RAB9ATHRB | |
| SCHEMBL28425942 | 0.72 | HPGD (0.57) | HPGDLMNATSHR | |
| SCHEMBL207794 | 0.72 | SMN1; SMN2 (0.70) | POLBALDH1A1SMN1; SMN2HPGDLMNA | |
| SCHEMBL2554154 | 0.71 | FFAR1 (0.61) | POLBALDH1A1HPGDTHRBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1745010-B1 | SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2009-08-05 | — | — | EP | claimed |
| US-20070112007-A1 | Cyclohexyl-1, 4-diamine compounds | GRUENENTHAL GMBH (DE) | 2007-05-17 | — | — | US | claimed |
| US-20070112007-A1 | Cyclohexyl-1, 4-diamine compounds | GRUENENTHAL GMBH (DE) | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112007-A1 | Cyclohexyl-1, 4-diamine compounds | PKD1, DDC, DPYD | POLB 1568/4885ALDH1A1 158/4885SMN1; SMN2 1061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.